US Congress House Bill 6033 (Prior Session Legislation)

---

Spectrum: Slight Partisan Bill (Democrat 2-1)
Status: Introduced on September 14 2016 - 25% progression, died in committee
Action: 2016-09-14 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]

Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)

Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

Rep. Scott Peters [D-CA]

Rep. Keith Rothfus [R-PA]

Rep. Brendan Boyle [D-PA]

Date	Chamber	Action
2016-09-14	House	Referred to the House Committee on Energy and Commerce.
2016-09-14	House	Introduced in House

Type	Source
Summary	https://www.congress.gov/bill/114th-congress/house-bill/6033/all-info
Text	https://www.congress.gov/114/bills/hr6033/BILLS-114hr6033ih.pdf